Stifel Nicolaus began coverage on shares of Pyxis Oncology (NASDAQ:PYXS – Free Report) in a research note issued to investors on Thursday, Marketbeat.com reports. The firm issued a buy rating and a $10.00 price objective on the stock.
Other research analysts have also recently issued reports about the company. Jefferies Financial Group reissued a buy rating and set a $10.00 price objective on shares of Pyxis Oncology in a report on Tuesday, May 7th. HC Wainwright restated a buy rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday, May 16th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of Buy and a consensus target price of $9.00.
Read Our Latest Research Report on PYXS
Pyxis Oncology Price Performance
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last issued its quarterly earnings data on Saturday, May 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. The company had revenue of $16.15 million for the quarter, compared to the consensus estimate of $4.25 million. Research analysts expect that Pyxis Oncology will post -1.09 EPS for the current fiscal year.
Institutional Trading of Pyxis Oncology
A number of hedge funds and other institutional investors have recently made changes to their positions in PYXS. Fullcircle Wealth LLC acquired a new stake in Pyxis Oncology in the second quarter worth about $40,000. SG Americas Securities LLC acquired a new stake in Pyxis Oncology in the first quarter worth about $59,000. Cetera Advisors LLC acquired a new stake in Pyxis Oncology in the first quarter worth about $100,000. Schulhoff & Co. Inc. increased its position in Pyxis Oncology by 90.9% in the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after purchasing an additional 20,000 shares during the period. Finally, American Century Companies Inc. increased its position in Pyxis Oncology by 56.0% in the second quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock worth $193,000 after purchasing an additional 20,901 shares during the period. 39.09% of the stock is currently owned by institutional investors and hedge funds.
About Pyxis Oncology
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Recommended Stories
- Five stocks we like better than Pyxis Oncology
- ETF Screener: Uses and Step-by-Step Guide
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- Stock Sentiment Analysis: How it Works
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.